Published in Nat Med on June 01, 1996
The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci U S A (2003) 6.79
Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol (1997) 5.09
Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax (2000) 4.85
Correlation between plasmid content and infectivity in Borrelia burgdorferi. Proc Natl Acad Sci U S A (2000) 4.81
From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J Bacteriol (2002) 4.66
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (1997) 3.75
Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother (1997) 3.46
Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis. J Clin Microbiol (2002) 3.32
Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother (2000) 3.27
Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis (1998) 3.05
PCR-based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions. J Clin Microbiol (2003) 3.02
Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res (2012) 2.81
Differentiation of clinical Mycobacterium tuberculosis complex isolates by gyrB DNA sequence polymorphism analysis. J Clin Microbiol (2000) 2.77
Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J Clin Microbiol (1999) 2.65
Differentiation among members of the Mycobacterium tuberculosis complex by molecular and biochemical features: evidence for two pyrazinamide-susceptible subtypes of M. bovis. J Clin Microbiol (2000) 2.64
PCR identification of Mycobacterium bovis BCG. J Clin Microbiol (1997) 2.60
Novel genetic polymorphisms that further delineate the phylogeny of the Mycobacterium tuberculosis complex. J Bacteriol (2006) 2.55
Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol (1999) 2.47
Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J Clin Microbiol (1999) 2.46
ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2003) 2.31
Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet (2014) 2.29
Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol (1998) 2.28
The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res (2001) 2.25
Evolution and clonal traits of Mycobacterium tuberculosis complex in Guinea-Bissau. J Clin Microbiol (1999) 2.23
Evaluation of genotype MTBC assay for differentiation of clinical Mycobacterium tuberculosis complex isolates. J Clin Microbiol (2003) 2.21
Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS One (2009) 2.20
Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol (1997) 2.18
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother (2009) 2.15
Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2000) 2.15
pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother (2000) 2.10
Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother (1999) 2.09
Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol (2006) 2.06
Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J Clin Microbiol (2002) 1.98
Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol (2008) 1.88
Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis (2013) 1.78
Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (2009) 1.75
A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother (2009) 1.74
Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 1.69
Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (2011) 1.67
Allele-specific PCR method based on pncA and oxyR sequences for distinguishing Mycobacterium bovis from Mycobacterium tuberculosis: intraspecific M. bovis pncA sequence polymorphism. J Clin Microbiol (1998) 1.66
Converting cancer therapies into cures: lessons from infectious diseases. Cell (2012) 1.65
Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother (2011) 1.62
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 1.59
Mycobacterium bovis subsp. caprae caused one-third of human M. bovis-associated tuberculosis cases reported in Germany between 1999 and 2001. J Clin Microbiol (2003) 1.59
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob Agents Chemother (2007) 1.58
Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin Microbiol (2012) 1.55
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother (1999) 1.53
Direct detection and identification of Mycobacterium tuberculosis and Mycobacterium bovis in bovine samples by a novel nested PCR assay: correlation with conventional techniques. J Clin Microbiol (2005) 1.53
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol (2002) 1.52
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol (2000) 1.51
Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J Clin Microbiol (2001) 1.46
Discovery of a novel Mycobacterium tuberculosis lineage that is a major cause of tuberculosis in Rio de Janeiro, Brazil. J Clin Microbiol (2007) 1.45
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J Clin Microbiol (2012) 1.39
Infection of red deer, cattle, and humans with Mycobacterium bovis subsp. caprae in western Austria. J Clin Microbiol (2002) 1.37
Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2008) 1.37
Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol (2012) 1.31
The Guinea-Bissau family of Mycobacterium tuberculosis complex revisited. PLoS One (2011) 1.30
Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect (2013) 1.30
Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) (2009) 1.29
Molecular markers demonstrate that the first described multidrug-resistant Mycobacterium bovis outbreak was due to Mycobacterium tuberculosis. J Clin Microbiol (1999) 1.28
Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One (2011) 1.27
Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry (2006) 1.27
Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother (2011) 1.24
New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (2000) 1.24
Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. J Clin Microbiol (2007) 1.22
Multiplex real-time PCR assay for rapid identification of Mycobacterium tuberculosis complex members to the species level. J Clin Microbiol (2008) 1.21
Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis. J Bacteriol (1998) 1.20
NAD+ auxotrophy is bacteriocidal for the tubercle bacilli. Mol Microbiol (2010) 1.19
Microbial NAD metabolism: lessons from comparative genomics. Microbiol Mol Biol Rev (2009) 1.17
Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chemother (2003) 1.17
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob Agents Chemother (2004) 1.17
Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother (1999) 1.16
Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med (2009) 1.16
Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol (2010) 1.14
Isolation and characterization of mini-Tn5Km2 insertion mutants of Brucella abortus deficient in internalization and intracellular growth in HeLa cells. Infect Immun (2003) 1.14
Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 1.13
Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. Biochem J (2001) 1.10
Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. Chem Biol (2013) 1.10
Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat Genet (2016) 1.09
Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker? Tuberc Res Treat (2015) 1.08
A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother (1997) 1.07
Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. J Clin Microbiol (2009) 1.06
Dynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatment. PLoS One (2011) 1.06
Use of the hupB gene encoding a histone-like protein of Mycobacterium tuberculosis as a target for detection and differentiation of M. tuberculosis and M. bovis. J Clin Microbiol (2004) 1.06
Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting. J Clin Microbiol (2003) 1.06
pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect Dis (2001) 1.06
Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J Bacteriol (2000) 1.05
Temperature-mediated heteroduplex analysis performed by using denaturing high-performance liquid chromatography to identify sequence polymorphisms in Mycobacterium tuberculosis complex organisms. J Clin Microbiol (2002) 1.04
Identification and genotyping of Mycobacterium tuberculosis complex species by use of a SNaPshot Minisequencing-based assay. J Clin Microbiol (2010) 1.04
In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother (1998) 1.03
Crystal structure of the yeast nicotinamidase Pnc1p. Arch Biochem Biophys (2007) 1.03
A promoter mutation causes differential nitrate reductase activity of Mycobacterium tuberculosis and Mycobacterium bovis. J Bacteriol (2004) 1.03
A single-step sequencing method for the identification of Mycobacterium tuberculosis complex species. PLoS Negl Trop Dis (2008) 1.03
Frequency of Mycobacterium bovis as an etiologic agent in extrapulmonary tuberculosis in HIV-positive and -negative Mexican patients. Eur J Clin Microbiol Infect Dis (2008) 1.01
Distinct genotypic profiles of the two major clades of Mycobacterium africanum. BMC Infect Dis (2010) 1.00
Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS Infect Dis (2015) 1.00
Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax (1998) 0.99
Electric field effect in atomically thin carbon films. Science (2004) 45.10
Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell (2000) 17.44
Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature (1999) 16.97
IntAct--open source resource for molecular interaction data. Nucleic Acids Res (2006) 13.82
Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science (2000) 13.62
Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol (2000) 11.62
Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med (2000) 11.12
Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell (2000) 11.09
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Smoking in China: findings of the 1996 National Prevalence Survey. JAMA (1999) 8.67
Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell (2001) 8.60
Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med (1995) 8.51
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38
Mammalian sweet taste receptors. Cell (2001) 8.04
Disruption of IRS-2 causes type 2 diabetes in mice. Nature (1998) 7.94
The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health (1994) 7.38
Rapid modification of bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res (1999) 6.85
Significant acidification in major Chinese croplands. Science (2010) 6.68
TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun (1999) 6.33
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (2001) 6.23
Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest (1999) 6.13
Cloning of mammalian Ire1 reveals diversity in the ER stress responses. EMBO J (1998) 5.96
An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum (1998) 5.72
MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet (1999) 5.61
Smads: transcriptional activators of TGF-beta responses. Cell (1998) 5.33
Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science (2001) 5.25
Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med (1992) 5.05
Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell (2001) 5.04
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol (1998) 5.01
Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A (2000) 4.79
Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature (2000) 4.68
Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science (1996) 4.59
Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization. J Am Chem Soc (2001) 4.46
Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A (1997) 4.29
PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria. J Clin Microbiol (1995) 4.27
Orientation selectivity and the arrangement of horizontal connections in tree shrew striate cortex. J Neurosci (1997) 4.26
Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem (2001) 4.23
Specificity of the HP1 chromo domain for the methylated N-terminus of histone H3. EMBO J (2001) 4.23
Novel gp91(phox) homologues in vascular smooth muscle cells : nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res (2001) 4.22
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med (2001) 4.22
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A (1994) 4.21
Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol (1998) 4.17
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum (1997) 4.08
The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med (1993) 4.04
From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor. Proc Natl Acad Sci U S A (1998) 3.99
Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care (1996) 3.96
The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum (1995) 3.93
Molecular dynamics simulations of a lipid bilayer and of hexadecane: an investigation of membrane fluidity. Science (1993) 3.81
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
High-level semi-synthetic production of the potent antimalarial artemisinin. Nature (2013) 3.80
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (1997) 3.75
Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. J Virol (2000) 3.70
Extent and distribution of linkage disequilibrium in three genomic regions. Am J Hum Genet (2000) 3.68
DNA large restriction fragment patterns of sporadic and epidemic nosocomial strains of Mycobacterium chelonae and Mycobacterium abscessus. J Clin Microbiol (1993) 3.65
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Discovery of a three-dimensional topological Dirac semimetal, Na3Bi. Science (2014) 3.54
Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother (1997) 3.46
Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A (1995) 3.33
Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res (1993) 3.31
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci U S A (1993) 3.24
Role of IRS-2 in insulin and cytokine signalling. Nature (1995) 3.23
Cell-cycle arrest versus cell death in cancer therapy. Nat Med (1997) 3.18
The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res (2001) 3.18
Cloning and expression of a rat brain L-glutamate transporter. Nature (1992) 3.14
Evidence that RME-1, a conserved C. elegans EH-domain protein, functions in endocytic recycling. Nat Cell Biol (2001) 3.10
Crystal structure of the two-RRM domain of hnRNP A1 (UP1) complexed with single-stranded telomeric DNA. Genes Dev (1999) 3.08
A mutation in Rab27a causes the vesicle transport defects observed in ashen mice. Proc Natl Acad Sci U S A (2000) 3.07
The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res (1995) 3.04
The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology (2009) 3.03
Immunodominant major outer membrane proteins of Ehrlichia chaffeensis are encoded by a polymorphic multigene family. Infect Immun (1998) 3.02
Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest (1999) 2.95
Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother (1996) 2.92
A class-wide phylogenetic assessment of Dothideomycetes. Stud Mycol (2009) 2.91
The MinE ring required for proper placement of the division site is a mobile structure that changes its cellular location during the Escherichia coli division cycle. Proc Natl Acad Sci U S A (2001) 2.90
A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology (1996) 2.86
Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology (1997) 2.84
The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev (1998) 2.82
Techniques: Recombinogenic engineering--new options for cloning and manipulating DNA. Trends Biochem Sci (2001) 2.79
Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab (1996) 2.78
Cancer risk and tetrachloroethylene-contaminated drinking water in Massachusetts. Arch Environ Health (1993) 2.75
Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol (1993) 2.72
Room-temperature quantum Hall effect in graphene. Science (2007) 2.71
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A (1998) 2.71
A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1996) 2.70
Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother (1997) 2.70
Evidence of bacterial metabolic activity in culture-negative otitis media with effusion. JAMA (1998) 2.58
Transformation of mycobacterial species using hygromycin resistance as selectable marker. Microbiology (1994) 2.55
Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther (2001) 2.53
Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med (2001) 2.53
Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity. EMBO J (1997) 2.49
The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature (1994) 2.49
Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Circ Res (1998) 2.49
The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev (2001) 2.48
Complete genome sequence of the genetically tractable hydrogenotrophic methanogen Methanococcus maripaludis. J Bacteriol (2004) 2.47
Identification and cloning of a negative regulator of systemic acquired resistance, SNI1, through a screen for suppressors of npr1-1. Cell (1999) 2.46
Evidence for a Mendelian gene in a segregation analysis of generalized radiographic osteoarthritis: the Framingham Study. Arthritis Rheum (1998) 2.45